lundi 16 avril 2018

Onco Actu du 16 avril 2018

1. Biologie

Why some cancers are 'born to be bad' [BBC News]

Deadly tumours are often born of childhood mutations [Nature]

3. Prévention

Seven ways ... to prevent bowel cancer [The Guardian]

3.3 Prévention - Vaccins

Merck's supply of HPV shot Gardasil 9 is running short in the U.K. [FiercePharma]

4. Dépistage, diagnostic et pronostic

2018 France Hospital Cancer Diagnostics Market: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review [ReportsnReports]

Unclear if cancer test funding is being used as intended [Cancer Research UK]

4.2 Dép., diag. & prono. - Génome

Researcher Presents Promising Early Results on Color Cascade Testing Uptake at ACMG Meeting [Genome Web]

Estonia Offers Free Genetic Testing to Residents [The Scientist]

Employees Jump at Genetic Testing. Is That a Good Thing? [NY Times]

4.9 Dép., diag. & prono. - Sein

Don’t Tell Me My DCIS Isn’t Cancer! [DNA Science Blog]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies [BMS]

Bristol Partners With Illumina On Diagnostic Test To Use With Opdivo [Forbes]

5.12.3 Immunothérapies-combinaisons

Focused Radiation May Help Turn on the Immune System [The Sentinel]

5.12.7 Immunothérapies - vaccins

Penn team spotlights a pilot ovarian cancer trial and survival rates for a personalized cancer vaccine [EndPoints]

5.2 Pharma

Hanmi calls time on troubled Tagrisso rival olmutinib [FierceBiotech]

5.6.4 ESMO - Poumon

1st-line Tagrisso demonstrates sustained benefit post progression in patients with EGFR-mutated non-small cell lung cancer [AstraZeneca]

ELCC 2018 News: New Data Support First-Line Osimertinib in Patients with NSCLC and Sensitising EGFR Mutation [ESMO]

ELCC 2018 News: Low Baseline Endoglin Levels May Signal Improved Survival with Nintedanib in Malignant Pleural Mesothelioma [ESMO]

5.9 AACR

Two Global Cancer Leaders Announce Ambitious Strategic Alliance [AACR]

5.9.1 AACR - sein

Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR [Merck]

5.9.11 AACR - SNC

NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary [NewLink Genetics]

5.9.3 AACR - mélanome

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma [Merck]

Pembrolizumab Reduced the Risk for Recurrence of Stage 3 Melanoma [AACR]

#AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda [EndPoints]

5.9.4 AACR - poumon

Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC) [BMS]

5.9.6 AACR - prostate

Too Much of a Good Thing: Effect of Prostate Cancer Gene Can Go Either Way, Roswell Park Researchers Find [Roswell Park]

5.9.7 AACR - divers

Fred Hutch scientists to feature next-generation T-cell therapies, big data, precision medicine and more at AACR [Fred Hutch]

Children with Non-chromosomal Birth Defects Face Higher Risk of Several Childhood Cancers [AACR]

Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor [AACR]

Birth Defects Linked to Increased Risk of Childhood Cancer [The Scientist]

5.9.8 AACR - Pharma

Selective Inhibitor Shows Early Promise in Patients With RET-altered Cancers [AACR]

Blueprint Medicines' Cancer Drug Impresses In Early Study [Forbes]

5.9.9 AACR - immunothérapies

With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge [FiercePharma]

For Cancer Drugs, Will Monday's Data Be As Good As It Gets? [Forbes]

6.5 Médecines alternatives

fake médicine: Science-based medicine versus homeopathy in France [Respectful Insolence]

6.7.1 IA/bioinformatique

IBM Watson Artificial Intelligence System for Cancer Care: Interview with Elekta’s Andrew Wilson [MedGadget]

6.9 Controverses

J&J Baby Powder litigation takes new focus with asbestos claims [Reuters]

Contest models highlight inefficiencies of scientific funding [arXiv]